LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.64 -1.8

Buy Sell

Overview

Share price change

24h

Current

Min

1.6099999999999999

Max

1.71

Key metrics
By Trading Economics
Income	17M -26M
EPS	-0.43
Profit margin	-2,190.837
Employees	171
EBITDA	14M -28M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+78.57% upside

Market Stats
By TradingEconomics
Market Cap	-3M 100M
Previous open	3.44
Previous close	1.64

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 18:59 UTC

Major Market Movers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 lis 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 lis 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 lis 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 lis 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 lis 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Rev $2.6B >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q EPS $4.02 >TCOM

17 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Adj EPS 26c >JHX

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 lis 2025, 21:39 UTC

Earnings

James Hardie Industries 2Q Sales $1.29B >JHX

17 lis 2025, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 21:38 UTC

Earnings

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q EPS BRL2.47 >XP

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q Rev BRL4.67B >XP

17 lis 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lis 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 lis 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 lis 2025, 19:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 18:20 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 lis 2025, 16:45 UTC

Acquisitions, Mergers, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 lis 2025, 16:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 16:15 UTC

Earnings

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 lis 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 lis 2025, 15:22 UTC

Acquisitions, Mergers, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 lis 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

78.57% upside

12 Months Forecast

Average 3 USD 78.57%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.